KaloBios Pharmaceuticals Inc Share Price Nasdaq
Equities
US48344T2096
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- USD | - |
01/05 | Combined Hearing for Disclosure Statement and Plan Approved for Humanigen, Inc. | CI |
12/04 | Combined Liquidation Plan and Disclosure Statement Filed by Humanigen, Inc. | CI |
Sales 2021 | 3.6 300.29 | Sales 2022 | 2.51 209.99 | Capitalization | 14.29M 1.19B |
---|---|---|---|---|---|
Net income 2021 | -237M -19.8B | Net income 2022 | -70M -5.85B | EV / Sales 2021 | 5,35,17,059 x |
Net cash position 2021 | 45.01M 3.76B | Net cash position 2022 | 10.16M 848M | EV / Sales 2022 | 16,44,636 x |
P/E ratio 2021 |
-0.92
x | P/E ratio 2022 |
-0.15
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 89.65% |
Managers | Title | Age | Since |
---|---|---|---|
Cameron Durrant
CEO | Chief Executive Officer | 63 | 07/16/07 |
Omar Ahmed
CTO | Chief Tech/Sci/R&D Officer | - | - |
Dale B. Chappell
CTO | Chief Tech/Sci/R&D Officer | 53 | 06/20/06 |
Members of the board | Title | Age | Since |
---|---|---|---|
Cameron Durrant
CEO | Chief Executive Officer | 63 | 07/16/07 |
Dale B. Chappell
CTO | Chief Tech/Sci/R&D Officer | 53 | 06/20/06 |
Ronald Barliant
BRD | Director/Board Member | 78 | 07/16/07 |
1st Jan change | Capi. | |
---|---|---|
+7.46% | 100B | |
+11.97% | 42.34B | |
-11.34% | 32.76B | |
+79.34% | 29.46B | |
-12.18% | 16.31B | |
+3.52% | 14.39B | |
-1.90% | 12.23B | |
+178.17% | 10.47B | |
+1.80% | 8.97B |